Halozyme Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Halozyme Therapeutics
HALO Stock  USD 69.87  0.65  0.94%   
Halozyme Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Halozyme Therapeutics' valuation are provided below:
Gross Profit
980.8 M
Profit Margin
0.4791
Market Capitalization
8.2 B
Enterprise Value Revenue
7.2618
Revenue
1.2 B
We have found one hundred twenty available fundamental trends for Halozyme Therapeutics, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to confirm Halozyme Therapeutics' regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 27th of January 2026, Market Cap is likely to grow to about 2 B. Also, Enterprise Value is likely to grow to about 2 B

Halozyme Therapeutics Total Revenue

1.23 Billion

Check Halozyme Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Halozyme Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 98.2 M, Interest Expense of 21.8 M or Selling General Administrative of 186.4 M, as well as many indicators such as Price To Sales Ratio of 6.52, Dividend Yield of 0.0 or PTB Ratio of 18.21. Halozyme financial statements analysis is a perfect complement when working with Halozyme Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Halozyme Stock
Check out the analysis of Halozyme Therapeutics Correlation against competitors.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.

Halozyme Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.5 B2.4 B860.3 M
Slightly volatile
Other Current Liabilities155.6 M148.2 M53.9 M
Slightly volatile
Total Current Liabilities168 M160 M107 M
Slightly volatile
Cash83.6 M133.2 M97.1 M
Slightly volatile
Cash And Short Term Investments719.8 M685.5 M336.9 M
Slightly volatile
Common Stock Total Equity104.5 K155.2 K122.3 K
Slightly volatile
Common Stock Shares Outstanding106.3 M148.8 M122.3 M
Slightly volatile
Liabilities And Stockholders Equity2.5 B2.4 B860.3 M
Slightly volatile
Other Stockholder Equity2.6 M2.8 M333.5 M
Slightly volatile
Total Liabilities2.1 B2 B715.4 M
Slightly volatile
Total Current Assets1.3 B1.2 B527.8 M
Slightly volatile
Common Stock107.2 K141.4 K120.5 K
Slightly volatile
Short and Long Term Debt Total1.8 B1.7 B617.4 M
Slightly volatile
Accounts Payable12.4 M11.8 M6.5 M
Slightly volatile
Property Plant And Equipment Net90.6 M86.3 M27.3 M
Slightly volatile
Non Current Assets Total1.2 B1.1 B332.5 M
Slightly volatile
Non Currrent Assets Other97.3 M92.7 M22.3 M
Slightly volatile
Inventory171.3 M163.1 M53.9 M
Slightly volatile
Property Plant And Equipment Gross121.3 M115.5 M35.1 M
Slightly volatile
Property Plant Equipment91.3 M86.9 M27.4 M
Slightly volatile
Net Receivables372.5 M354.7 M110.9 M
Slightly volatile
Other Liabilities26.6 M16 M26.4 M
Slightly volatile
Non Current Liabilities Total1.9 B1.8 B609.5 M
Slightly volatile
Capital Surpluse29.9 M31.5 M354.3 M
Slightly volatile
Long Term Debt Total1.8 B1.7 B619.7 M
Slightly volatile
Capital Lease Obligations1.2 M1.3 M1.4 M
Slightly volatile
Non Current Liabilities Other66.1 M63 M16.9 M
Slightly volatile
Short and Long Term Debt14.6 M15.3 M60.8 M
Very volatile
Short Term Debt7.2 M7.6 M59.1 M
Very volatile
Net Invested Capital1.1 B2.2 B832.9 M
Slightly volatile
Net Working Capital583.9 M1.1 B504.2 M
Slightly volatile
Capital Stock107.4 K110.7 K136.4 K
Slightly volatile

Halozyme Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative186.4 M177.5 M76.2 M
Slightly volatile
Selling And Marketing Expenses588315407
Slightly volatile
Total Revenue1.2 B1.2 B399.1 M
Slightly volatile
Gross Profit1 B984.3 M330.2 M
Slightly volatile
Other Operating Expenses560.1 M533.4 M252.4 M
Slightly volatile
Cost Of Revenue192.5 M183.3 M68.9 M
Slightly volatile
Total Operating Expenses367.6 M350.1 M183.5 M
Slightly volatile
Research Development77.6 M90.9 M85.7 M
Very volatile
Interest Income4 M4.2 M6.7 M
Pretty Stable
Reconciled Depreciation98.2 M93.5 M25.7 M
Slightly volatile

Halozyme Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow83.8 M133.2 M97.3 M
Slightly volatile
Begin Period Cash Flow81.9 M136.1 M95.4 M
Slightly volatile
Depreciation107.1 M102 M27.3 M
Slightly volatile
Stock Based Compensation52.4 M49.9 M25.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.526.8724.7086
Slightly volatile
Days Sales Outstanding167128154
Slightly volatile
Average Payables2 M2.4 M2.7 M
Very volatile
Stock Based Compensation To Revenue0.04670.04910.1332
Slightly volatile
Capex To Depreciation0.130.140.7931
Slightly volatile
EV To Sales8.028.4425.3187
Slightly volatile
Inventory Turnover1.311.011.6226
Very volatile
Days Of Inventory On Hand574374473
Slightly volatile
Payables Turnover14.714.010.8176
Slightly volatile
Sales General And Administrative To Revenue0.440.460.4929
Slightly volatile
Average Inventory1.5 M1.5 M1.4 M
Slightly volatile
Research And Ddevelopement To Revenue0.08510.08955.3176
Slightly volatile
Capex To Revenue0.01150.01210.1784
Slightly volatile
Cash Per Share4.444.232.4123
Slightly volatile
Days Payables Outstanding25.6426.99746
Slightly volatile
Income Quality0.690.971.0081
Pretty Stable
Intangibles To Total Assets0.530.460.5086
Slightly volatile
Current Ratio6.728.975.5574
Slightly volatile
Receivables Turnover6.413.796.2198
Slightly volatile
Graham Number14.2113.536.5099
Slightly volatile
Capex Per Share0.07970.07590.0348
Slightly volatile
Average Receivables11.7 M11.2 M11 M
Slightly volatile
Revenue Per Share7.577.212.8245
Slightly volatile
Interest Debt Per Share11.3510.814.4554
Slightly volatile
Debt To Assets0.460.660.5284
Slightly volatile
Operating Cycle733501626
Slightly volatile
Days Of Payables Outstanding25.6426.99746
Slightly volatile
Ebt Per Ebit1.11.1659.5909
Slightly volatile
Long Term Debt To Capitalization0.590.720.6944
Pretty Stable
Total Debt To Capitalization0.620.720.722
Pretty Stable
Quick Ratio6.477.85.1706
Pretty Stable
Net Income Per E B T0.740.720.9174
Very volatile
Cash Ratio0.910.961.8688
Slightly volatile
Days Of Inventory Outstanding574374473
Slightly volatile
Days Of Sales Outstanding167128154
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.961.121.0798
Slightly volatile
Fixed Asset Turnover16.4212.1824.6816
Very volatile
Debt Ratio0.460.660.5284
Slightly volatile
Price Sales Ratio6.526.8724.7086
Slightly volatile
Asset Turnover0.340.440.5106
Slightly volatile
Gross Profit Margin0.610.760.7938
Very volatile

Halozyme Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2 B1.9 B1.6 B
Slightly volatile
Enterprise Value2 B2 B1.7 B
Slightly volatile

Halozyme Fundamental Market Drivers

Forward Price Earnings8.3403
Cash And Short Term Investments596.1 M

Halozyme Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Halozyme Therapeutics Financial Statements

Halozyme Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Halozyme Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-29 M-27.5 M
Total Revenue1.2 B1.2 B
Cost Of Revenue183.3 M192.5 M
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.46  0.44 
Research And Ddevelopement To Revenue 0.09  0.09 
Capex To Revenue 0.01  0.01 
Revenue Per Share 7.21  7.57 
Ebit Per Revenue 0.49  0.51 

Pair Trading with Halozyme Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Halozyme Stock

  0.62VYGR Voyager TherapeuticsPairCorr
  0.62LRMR Larimar TherapeuticsPairCorr
  0.61MREO Mereo BioPharma GroupPairCorr
  0.52REVB Revelation BiosciencesPairCorr
  0.47SLN Silence Therapeutics PLCPairCorr
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock:
How To Invest In Halozyme
Details
Is Halozyme Stock a good investment?
Details
What is Halozyme Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Halozyme Therapeutics Correlation against competitors.
To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.
You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.362
Earnings Share
4.74
Revenue Per Share
10.185
Quarterly Revenue Growth
0.221
Return On Assets
0.2124
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY